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Abstract
Background: The efficacy of inhaled corticosteroids (ICS) in moderately severe COPD patients remains
unclear. At the same time, the use of extrafine particles in COPD patients is a topic of ongoing research.
Objectives: This study assessed the effect of ICS in steroid-naı¨ve mild COPD patients and the effect of reducing
the ICS dose in more severe COPD patients previously using ICS when switching to an extrafine particle BDP/F
formulation (Foster using Modulite technology, Chiesi Pharmaceutici, Parma, Italy).
Methods: Novel functional respiratory imaging (FRI) methods, consisting of multi-slice CT scans and Com-
putational Fluid Dynamics, were used in combination with conventional pulmonary function tests and patient
reported outcomes.
Results: The study showed that the administration of extrafine BDP/F after 4–6 h led to a significant im-
provement in lung function parameters and hyperinflation as determined by spirometry, body plethysmography,
and functional respiratory imaging. After 6 months of treatment, it was observed that, compared to baseline, the
hyperinflation on lobar level at total lung capacity was significantly reduced (- 1.19– 7.19 %p, p¼0.009). In
addition, a significant improvement in SGRQ symptom score was noted in the entire patient population. Patients
who improved in terms of hyperinflation also improved their MMRC dyspnea score. CFD indicated a difference
in regional deposition between extrafine and non-extrafine formulations with - 11% extrathoracic deposition
and up to + 4% lobe deposition for the extrafine formulation.
Conclusions: The study showed that the administration of extrafine BDP/F improved lung function parameters
and hyperinflation. Patients previously treated with ICS remained stable despite the lower dose, while ICS naı¨ve
patients improved in terms of lobar hyperinflation. FRI seems to be a sensitive biomarker to detect clinically
relevant changes that are not detected by spirometry. The next step is to confirm these findings in a controlled trial.
Introduction
Chronic obstructive pulmonary disease (COPD) isa multicomponent disease that includes airway in-
flammation, airflow limitation, mucociliary dysfunction,
and airway structural changes.(1) The hallmark of COPD
is, beside the destruction of the lung tissue and capillaries,
expiratory flow limitation, which is slowly progressive and
irreversible.(2–4) Specific lung function tests, including flow-
volume loops, N2 wash-out, and helium flow-volume
loops, are typically performed to evaluate the small airway
function.(5) Recently, advanced imaging techniques such as
multi-slice high resolution CT have been used.(6) This tech-
nique allows evaluation of the density of the parenchyma and
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reconstruction of the airways in 3D. Very recently, we de-
veloped a functional respiratory imaging (FRI) technique
combining CT imaging with computational fluid dynamics
(CFD). With CFD, based on the CT-derived geometry of the
airways, it became possible not only to reconstruct the ge-
ometry of the distal airways but also to measure the overall
resistance of airways and regional aerosol deposition char-
acteristics at the more peripheral level such as the smaller
airways starting from the third bifurcation. Lung volumes can
be assessed in more detail at the lobar level, leading to a more
granular description of hyperinflation. In previous studies, we
demonstrated very good correlations between spirometric
indices such as Forced Expiratory Volume in one second
(FEV1) and FEV1/FVC (Forced Vital Capacity) index with
the FRI parameters. Therefore, the use of FRI may allow
following the functional and anatomic changes in the small
Table 1. Patient Demographics and Baseline
Pre-Bronchodilation Lung Function and SGRQ
GOLD II
(n= 15)
GOLD III
(n = 8)
GOLD IV
(n = 4)
Age [years] 64.67– 8.06 62.37– 7.11 67.25– 12.28
FEV1
[%pred]
52.94– 11.38 37.25– 10.07 38.25– 16.50
FEV1/VC
[%]
43.13– 9.43 35.00– 8.37 40.00– 13.78
SGRQ [-] 44.52– 16.78 44.79– 15.10 48.15– 11.07
FRC
[%pred]
150.27– 28.07 160.13– 28.27 146.50– 48.86
TLC
[%pred]
121.13– 17.92 117.50– 16.56 114.50– 34.31
Table 2. Medication Prior to Study Inclusion and Associated Inhalers
Nr Age Gender Stage
Lung medication
before V1 Nr Age Gender Stage Lung medication before V1
1 60 M GOLD 3 Serevent 25lg 2 · 1/day
Spiriva
15 68 M GOLD 3 Oxis 9 lg 2 · 1/day
Spiriva
Duovent PRN
Pulmicort 200lg, 2 · 2/day
2 53 M GOLD 4 Seretide 25lg/250 lg
2· 2/day
Spiriva
Duovent PRN
16 64 F GOLD 3 Spiriva
Seretide 50 lg/500 lg 2 · 1/day
3 81 M GOLD 4 Serevent 50lg 1 · /day
Spiriva
17 73 M GOLD 2 Spiriva
Acetylcysteı¨ne 600mg
Ventolin PRN
4 63 F GOLD 2 Spiriva 18 51 F GOLD 2 Spiriva
Seretide 25/250 2 · 2/day
Duovent PRN
5 65 M GOLD 3 Seretide 50lg/500 lg
2· 1/day
Spiriva
Duovent PRN
19 47 F GOLD 2 Spiriva
Serevent 50 lg 2 · 1/day
Ventolin PRN
6 48 M GOLD 3 Seretide 25lg/250 lg
2· 2/day
Spiriva
Duovent PRN
20 72 M GOLD 2 Symbicort 4,5 lg/160 lg
2 · 1/day
Spiriva
Duovent PRN
Acethylcsteı¨ne 600 mg
2 · /day
Montelukast 10mg
7 65 M GOLD 3 Seretide 50lg/500 lg
2· 1/day
Spiriva
Duovent PRN
21 65 M GOLD 2 Spiriva
Symbicort 4,5 lg/160 lg
2 · 2/day
Duovent PRN
8 73 M GOLD 2 Serevent 50lg 2 · 1/day
Spiriva
Duovent PRN
22 64 M GOLD 2 Seretide 50 lg/250 lg 2 · 1/day
Spiriva
9 64 M GOLD 2 Serevent 50lg 2 · 1/day
Spiriva
Duovent PRN
Acetylcysteı¨ne 600mg
23 63 F GOLD 2 Spiriva
Symbicort Forte 9 lg/320 lg
2 · 1/day
Duovent PRN puff and aerosol
Lysomucil 600 mg PRN
(continued)
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airways after pharmacological interventions both in asth-
matics and COPD patients.(7–10)
During the last 10 years, inhaled corticosteroids (ICS) and
long-acting b2 agonists (LABA) combination therapy has
come forward to treat COPD patients. The concomitant use of
ICS and LABA can influence airway obstruction, mucociliary
dysfunction, and airway inflammation.(1,11) Furthermore, use
of ICS in combination with LABA in a single inhaler shows
significant additional improvements on pulmonary function
and reduction in symptoms and exacerbations, compared with
individual components.(12–15) At present, the effect of inhaled
ICS/LABA combination on individual airways and lung
volumes remains unclear, and in particular, the effect of ICS
in moderate COPD is uncertain. The role of aerosol deposi-
tion and the influence of extrafine particles with a lower ICS
dose is subject of continuous research.(16,17) The current study
explored the effect of an extrafine particle BDP/F formulation
(Foster using Modulite technology, Chiesi Pharmaceutici,
Parma, Italy) in COPD patients after 6 month treatment using
pulmonary function tests and sensitive FRI tools, with spe-
cific focus on lobar and airway volumes and resistance, to
assess the effect at the level of small airways. Both steroid
naı¨ve (moderate COPD patients) and steroid users (severe
COPD patients) were included in the patient cohort to assess
the effect of extrafine particle ICS in moderate COPD.
Methods
Patients
This study enrolled 27 evaluable COPD patients stage II
to IV. Patients had a smoking history of at least 10 pack-
years and an FEV1/FVC ratio below 0.70. Male (n= 16) and
female (n = 11) patients were included with age above 40
years. All patients were treated according to the GOLD
guidelines before entering the study. Patient demographics
and characteristics according to GOLD classification can be
found in Table 1.
Study design
This study was an open-label, prospective pilot study. The
patients received the extrafine beclometasone dipropionate
and formoterol fumarate (BDP/F) combination therapy for 24
weeks. They were followed for 7 months before the start of
Table 2. (Continued)
Nr Age Gender Stage
Lung medication
before V1 Nr Age Gender Stage Lung medication before V1
10 61 F GOLD 2 Spiriva
Duovent PRN
24 68 F GOLD 2 Spiriva
Symbicort 9 lg/320 lg
2 · 1/day
11 62 F GOLD 4 Serevent 25 lg 3 · 1/day
Flixotide 250lg 3 · 2/day
Spiriva
Duovent 2 · 2/day
Xanthium 400mg 1 · /day
25 73 M GOLD 4 Seretide 25lg/250 lg 2· 2/day
Spiriva
Duovent PRN
Ventolin 100 lg PRN
always uses Volumatic
12 78 F GOLD 2 Oxis 9 lg 2 · 1/day 26 58 M GOLD 3 Spiriva
Serevent 25 lg 2· 2/day
Xnthium 400mg
Ventolin PRN
13 62 F GOLD 2 Oxis 9 lg 2 · 1/day
Spiriva
Duovent 2 · 2
27 66 M GOLD 2 Spiriva
Seretide 50/500 2 · 1/day
Duovent PRN
Theolair 350mg in the
morning
Theolair 250mg in the
evening
Montelukast
14 71 F GOLD 3 Spiriva
Seretide 50 lg/500 lg
2 · 1/day
Inhalers associated with the medication
Serevent 25 Evohaler
Serevent 50 Diskus
Spiriva Respimat
Duovent HFA MDI
Seretide 25/250 Evohaler
Seretide 50/250 Diskus
Symbicort 9/320 Turbuhaler
Symbicort 4.5/160 Turbuhaler
Ventolin 100 Evohaler
Pulmicort 200 Turbuhaler
Oxis Turbuhaler
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the study when they switched to the extrafine formulation.
During this 7-month period they were treated with inhaled
steroids or fixed combinations with a non-extrafine particle
formulation (i.e., no Foster or QVAR). Patients were evalu-
ated twice for their lung function and clinical status (at 7 and
3 months before the switch). At baseline visit, patients re-
ceived all tests (FRI, pulmonary function tests, and patient
reported outcomes) before and after bronchodilation. At the 6
months visit, patients again received all tests before bronch-
odilation (pre-dose).
Medication
The study medication (Foster, Chiesi Pharmaceutici, Italy)
is a fixed combination containing extrafine beclometasone
dipropionate and formoterol fumarate in a HFA Modulite
pMDI device (MMAD= 1.33; GSD= 1.97).18 Each metered
dose (ex-valve) contains 100 micrograms of beclometasone
dipropionate and 6 micrograms of formoterol fumarate di-
hydrate. In this study, patients inhaled the 6lg formoterol
and 100lg beclometasone dipropionate combination therapy
twice in the morning and twice in the evening.
Image post-processing
The CT settings used were: tube voltage, 120 kV; tube
current, 10 (low weight patients)–100 (high weight patients)
mAs; noise factor, 28; collimation, 0.625mm; rotation time,
0.6 sec; and pitch factor, 1.375. The field of view was indi-
cated by the CT technician based on the scout image and was
positioned closely around the thorax to optimize in-plane
image resolution, which was approximately 0.5mm. The re-
sulting radiation dose was in the order of 1–2 mSv per scan.
Images were reconstructed to a slice thickness of 0.6mm to
attain near cubic voxels. Respiratory gating was used to en-
sure the proper lung volume to facilitate comparison between
baseline and follow-up images. Post-processing of the CT
images included segmentation of the airway tree structure, the
lung lobes, and CFD flow simulations. Segmentation con-
sisted of grouping voxels that belong to one anatomical
structure such as the lung, the lobes, or the airway tree. This
group of voxels or mask can subsequently be used to create a
patient-specific three-dimensional model of the anatomical
structure under consideration. The software package that was
used was FDA-approved (Mimics, Materialise, Leuven,
Belgium). These patient specific models were the basis for
flow simulations using Computational Fluid Dynamics
(CFD). More details on the segmentation and CFD principles
can be found in previously published studies.(7–10,19)
Assessments
The parameters obtained with functional respiratory im-
aging and used as primary outcome were:
 Airway volumes specific for the lung volume (siVaw):
the airway volumes are direct measurement from the
CT scans and include the airways with a diameter lar-
ger then 1–2mm. Around 255 airways are typically
included in the patient specific geometry, which cor-
responds to around 7 generations of airways. The air-
way volume is a function of the lung volume. To allow
comparison of the volumes at different measurement
points, the airway volume is normalized by dividing by
the lobe volume. The same number of airways are present
the baseline and follow-up measurements (see Fig. 3).
 Specific airway resistance (siRaw): airway resistance is
calculated using CFD. CT-based lobe expansion from
expiration to inspiration was used as boundary condi-
tions to ensure the internal airflow distribution in the
CFD calculation matches the patient’s real internal
airflow distribution. CFD yields total pressure drops
and airflow, the resistance is ratio between the two.
More information can be found in De Backer et al.(19)
 Lobar volumes at functional residual capacity (iVlobes_
FRC).
 Lobar volumes at total lung capacity (iVlobes_TLC).
Lobar volumes are determined by first segmenting the
lung volumes and the fissures; subsequently the fissures are
used as cutting planes to determine the lobar volume.
The following parameters were obtained with the lung
function tests:
 Dynamic lung volumes: Forced expiratory volume in
one second (FEV1), forced vital capacity (FVC), peak
expiratory flow (PEF), Maximal expiratory flow at 50%
of expired vital capacity (MEF50), Maximal expiratory
flow at 25% of expired vital capacity (MEF25).
 Static lung volumes: Vital capacity (VC), Inspiratory
vital capacity (IVC), Functional residual capacity
(FRC), Total lung capacity (TLC).
 Airway resistances: Airway resistance (Raw), Specific
airway conductance (SGaw), based on body plethys-
mography.
Further assessments were:
 Functional dyspnea (MMRC dyspnea scale).
 Saint George Respiratory Questionnaire (SGRQ).
CFD based deposition analysis
To understand the changes in deposition when switching to
extrafine particles, a CFD-based deposition analysis was
performed in one patient. The baseline model was coupled
with the inhaler of the medication the patient previously used
(i.e., Oxis Turbuhaler; MMAD= 2.64; GSD= 1.91))(20) and
with the Foster inhaler. Two CFD-based deposition analysis
were performed using the methodology described and vali-
dated in De Backer et al.,(7) one with the original inhaler and
the corresponding formulation and one with the Foster inhaler
with the extrafine particle formulation. Since the main aim of
these simulations was to determine differences in deposition
due to particle size, the same inhalation profile was used for
both scenarios (3 second inhalation with 60L/min peak flow).
These analyses provided regional aerosol deposition charac-
teristics. No exhaled fraction was assumed for both scenarios.
Statistics
Statistical analysis was performed using Statistica 9.1
(StatSoft, Tulsa, OK, USA). Changes in individual param-
eters after 6 months of treatment with the study medication
were evaluated using Wilcoxon matched pairs analysis.
Correlations between the changes in different parameters
were evaluated using Spearman correlations. Stability of the
baseline 7-month period was evaluated with ANOVA. Data
are presented as mean – standard deviation.
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FIG. 2. Changes in FEV1, TLC, and
FRC 4 h at pre-dose and after drug
administration at Day 1 (left) and be-
tween pre-dose at D1 and after 6
months of treatment (right).
FIG. 1. FEV1 [L] at two time points prior to inclusion demonstrate that patients were
stable and controlled before entering the study.
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Ethics
Approval from the ethical committee of the University
Hospital in Antwerp was obtained and patients all gave their
informed consent (NCT01204034). The study started Sep-
tember 2010 and ended June 2012.
Results
Lung function during initial 7 month treatment
with non-extrafine particles
All patients were treated with non-extrafine particles
compounds during a 7-month period prior to the switch (Table
2). During this period, lung function measurements were
performed at 7 months and 3 months prior to the switch. The
results are given in Figure 1. There were no significant
changes in the FEV1 during this period, nor were patients
considered to be clinically unstable since their medication was
not altered and their symptoms did not change significantly.
Post-bronchodilation effect 4–6 h after administration
of extrafine particle compound
The data showed that, 4–6 h after the administration of the
drug, FEV1 % predicted values increased significantly from
46– 14% to 50– 15% ( p= 0.0003). Concomitantly, hyperin-
flation decreased significantly as indicated by a reduction in
FRC of 7– 10%pred ( p= 0.002). The TLC also decreased,
just missing the statistical significance threshold ( p= 0.06)
(Fig. 2). No differences were observed between the ICS naı¨ve
patients and the ICS users for the PFTs. The FRI data showed
a highly significant increase in siVaw (Fig. 3) from 0.0019–
0.001 to 0.0021– 0.001 ( p< 0.00001) and a highly significant
reduction in siRaw from 0.23– 0.26 kPas to 0.15– 0.11 kPas
( p< 0.00001) (Fig. 4). No differences were observed between
the ICS naı¨ve patients and the ICS users for siVaw and
siRaw. When assessing the changes in lobar volumes using
imaging, a significant reduction was observed both in iVlobes_
FRC and iVlobes_TLC (p< 0.00001). ICS naı¨ve patients re-
duce more in terms of acute iVlobes_FRC (p= 0.0045) and
iVlobes_TLC (p= 0.001) compared to the ICS users.
Pre-bronchodilation effect after 6 months of treatment
with the small particle compound
After 6 months of treatment, the pre-bronchodilation
measures were compared with the pre-bronchodilation val-
ues at baseline. Both spirometry (FEV1) and body plethys-
mography values (FRC and TLC) did not change significantly
(Fig. 2). Also no significant change in siVaw ( p= 0.65) and
siRaw ( p= 0.16) was observed (Fig. 4). However, interest-
ingly, the Wilcoxon matched pairs test on the imaging data at
the lobar level showed a significant reduction in lobar volume
at TLC (iVlobes_TLC, - 1.19– 7.19 %p, p= 0.009) (Fig. 5);
this change was driven by the ICS naı¨ve patients. A borderline
FIG. 3. Changes in siVaw [%] 4h after bronchodilation.
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but significant difference in iVlobes_TLC change between
ICS naı¨ve patients and ICS users was observed ( p= 0.044).
SGRQ symptoms score indicated a significant improvement
( p= 0.04) after 6 months (Fig. 6). The MMRC score showed a
link between the change in dyspnea feeling and the change
in lobar hyperinflation measured at TLC (iVlobes_TLC).
Patients who reported an improvement in MMRC score
equal or greater than 1 had a significantly greater ( p= 0.0024)
reduction lobar iVlobes_TLC volumes compared to patients
who reported a decline in MMRC by 1 or greater. The group
of patients who reported no change in MMRC score had no
reduction ( p> 0.05) in the lobar iVlobes_TLC level. No
difference in patient reported outcome changes were ob-
served between ICS naı¨ve patients and ICS users. When
comparing the change in pre-bronchodilation iVlobes_TLC
with the acute (4–6h) change in iVlobes_TLC, a significant
positive correlation (r= 0.44, p< 0.00001) was observed with
a slope of approximately 0.78 (Fig. 7). This would mean that
around 78% of the acute, post-bronchodilation change effec-
tively remains after 6 months of treatment. Furthermore, a
highly significant negative correlation (r= -0.40; p < 0.00001)
was found between the pre-bronchodilation iVlobes_FRC
and the acute change in iVlobes_FRC after drug intake. This
indicated that the more hyperinflated the patients were prior
to receiving the medication, the more they tend to deflate
with treatment (Fig. 8).
CFD-based deposition patterns
To assess the link between the change in deposition and the
change in lobar volume, CFD was used to determine the de-
position patterns in patient 14. Figure 9 illustrates the cou-
pling between the patient specific model of patient 14 and the
Oxis Turbuhaler and Foster pMDI. It could be observed that
the lung dose reaching the lower airways is larger for the
extrafine particle formulation compared to the non-extrafine
particle formulation with a reduction in extrathoracic depo-
sition of 11% and an increase in lobe deposition up to 4% for
FIG. 4. Changes in siVaw and siRaw at pre-dose and after drug administration at Day 1 (left) and between pre-dose and
Day 1 after 6 months of treatment (right).
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the extrafine particle formulation. Table 3 provides an over-
view of changes in deposition in relation to the changes in
hyperinflation for patient 14. For this patient, it appears that
more deposition correlates with reduction in hyperinflation.
Discussion
The current study aimed to investigate further the effect
of extrafine BDP/F on airways geometry using sensitive
image-based parameters in both ICS naı¨ve patients and ICS
users and to identify the responders. A recent study by Tzani
et al.(21) has indicated that the extrafine beclomethasone/
formoterol combination has a beneficial effect on hyperin-
flation in COPD patients studied using body plethysmog-
raphy (functional residual capacity, residual volume, and
total lung capacity). The effect appeared to be significantly
better than a fluticasone/salmeterol combination treatment.
The study concluded that, by using extrafine particles, pre-
viously suboptimally or untreated regions in the lung could
be reached, resulting in an enhanced efficiency. Other
studies have demonstrated the added value of combining
imaging and computational fluid dynamics to obtain
FIG. 6. Changes in SGRQ symptom score at baseline and after 6 months of treatment
recorded prior to bronchodilation.
FIG. 5. Changes in iVlobes_TLC (%pred) 4–6 h after bronchodilation (left,
p < 0.00001)) and after 6 months of treatment with extrafine BDP/F (right, p = 0.009)
compared to pre-bronchodilation baseline.
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regional information on airway and lobar volumes and re-
sistances.(8,10) The image-based outcome parameters in our
study confirmed the results from the previous study using
BDP/F by also indicating an improvement in lung function
and imaging parameters 4–6 h after the administration using
this novel imaging method in patients that were proven
clinically stable during at least 6 months when they were
treated with non-extrafine particle compounds. The current
study was a longitudinal study where subjects switched from
the standard therapy including high dose of ICS/LABA or
ICS naı¨ve to a new extrafine particle drug. Further im-
provement in lung function and symptoms was therefore not
FIG. 8. Change in iVlobes_FRC [%pred] 4–6 h after the administration as a function of
the baseline iVlobes_FRC [%pred].
FIG. 7. Change in iVlobes_TLC [%pred] after 6 months compared to pre-dose Day 1
as a function of the changes in iVlobes_TLC [%pred] 4–6 h after the administration on
Day 1.
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expected in the ICS users group, but adequatemaintenancewas
an anticipated end point of the study, which was reached. The
BDP/F combination used in this study contained a substantially
lower dose of ICS and LABA compared to the medication that
the patients received prior to the study. The enhanced lung dose
due to the smaller particles and the reduced risk of pneumonia
were the drivers for selecting this dose.(21)
The bodyplethysmography yields aggregate or global val-
ues of TLC and FRC while FRI provides lobar information. It
can happen that certain lobes reduce in hyperinflation but that
the neighboring lobe re-inflates, thereby limiting the signal in
the global (body box) parameters obtained using the body
box. Tzani et al.(21) reported significant post-dose improve-
ments in TLC and FRC after 12 weeks. Our study looked at
pre-dose TLC and FRC measurements over 6 months. Tzani’s
pre-dose values over 12 weeks were not significantly different,
which is in line with our findings. However, we did find sig-
nificant effects on reduction in FRC after acute bronchodila-
tion and a trend in reduction in TLC using plethysmography.
On a regional, lobar level (determined using FRI) these
findings become highly significant which in turn supports
Tzani’s overall conclusion.
The CFD-based aerosol deposition analysis showed how
the extrafine particles increase the effective lung dose and
reach other areas in the lung compared to non-extrafine
particle formulation. It must be stated that this analysis fo-
cused on the relative deposition differences based on the
emitted dose in one patient. More effective inhalers with a
larger emitted dose or different formulation characteristics
could yield higher overall lung deposition compared to less
effective devices. The fact that for the current analysis no
exhaled fraction is assumed could imply that the extrafine
particle deposition is overestimated. This will be the subject
of future research. The role of ICS in moderate COPD pa-
tients has always been a topic of ongoing research. The ICS
naı¨ve patients in our study, who were considered to be more
Table 3. CFD-Based Deposition and Change in Lobar Volumes for Patient 14
% deposition
Oxis
% deposition
Foster D deposition %
D Volume
FRC [%p]
D Volume
TLC [%p]
Right upper lobe 7 9 + 2 - 24 - 4
Right middle lobe 2 3 + 1 - 6 - 7
Right lower lobe 15 19 + 4 - 32 - 6
Left upper lobe 6 8 + 2 - 21 - 2
Left lower lobe 8 10 + 2 - 35 - 10
Extrathoracic 62 51 - 11 n/a n/a
FIG. 9. Coupling of patient 14’s airway geometry with the Oxis (left) and Foster
(right) inhaler.
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moderate COPD patients, actually benefited from the addi-
tion of ICS through a reduction in hyperinflation. After 6
months of treatment prior to bronchodilation, most param-
eters did not indicate a significant difference. Interestingly,
the lobar volumes at TLC did reduce significantly in the ICS
naı¨ve group. Even though the reduction was limited in ab-
solute terms, it was very consistent over all ICS naı¨ve pa-
tients and lobes and highly significant. Classic outcome
parameters such as body plethysmography cannot detect
these regional changes due to the inherent black box ap-
proach. The subtle redistribution of air between the lobes,
which appear to be driving the feeling of dyspnea and
symptoms, can only be detected using imaging methods that
provide regional characteristics of the respiratory system.
This could explain why the benefit of ICS in moderate
COPD patient is difficult to demonstrate using conventional
endpoints. The long-term effect of the product on lobar
volumes at TLC appeared to correlate well with the short-
term effect. Approximately 78% of the short-term post-
bronchodilation change is still present after 6 months prior
to bronchodilation. This in itself is again a hint that previ-
ously untreated areas are now potentially reached by the
compound, perhaps as a result of a redirection of incoming
air due to the reduction in air trapping.
The SGRQ symptom score also indicated that the patients
were feeling significantly better. It is well known that a
reduction in hyperinflation would lead to an improvement in
the patient reported outcome parameters. Therefore it
seemed plausible that the extrafine particles reached dif-
ferent lung zones to enhance the reduction in air trapping.
Patients who experienced a substantial reduction in hyper-
inflation (Fig. 5) also reported that they were feeling better
after 6 months, reinforcing the link between hyperinflation
and patient’s well being. This is further confirmed when
looking at the relation between the change in dyspnea
(MMRC) score and the change in lobar hyperinflation
measured at TLC. The MMRC questionnaire aims at as-
sessing the patient’s dyspnea on a score between 0 (best)
and 4 (worse). A reduction in this score therefore means the
patient is improving. Overall this score did not change
significantly, but in the subset of patients that reported an
improvement, the lobar volumes at TLC were reduced. The
correlation between the pre-dose lobar volumes at FRC at
baseline and the 4–6 h change also indicated that the more
severely hyperinflated patients tend to improve most.
The current study showed the potential of novel imaging
methods to provide a deeper insight into the mode of action
of a drug and detect features that previously could not be
analyzed due to the lack of sensitivity. Airway and lobe
volumes are direct measurements from the CT data, ob-
tained through segmentation, while the CFD method is used
to determine airway resistance and aerosol deposition
characteristics. Having the opportunity to assess parameters
on a lobar scale is a significantly improvement over the
existing techniques such as spirometry and body plethys-
mography, which typically use a black box approach. The
main focus of this trial was on the assessment of changes in
hyperinflation using imaging and the maintenance of re-
spiratory function using extrafine BDP/F in ICS naı¨ve pa-
tients and ICS users. Therefore, this trial did not include a
control arm; however it was assured that patients included in
the study were stable and controlled by assessing their lung
function twice over a 7-month period prior to inclusion. The
evidence is suggestive that the observed effects are induced
by the treatment. However, future controlled studies need to
further confirm these results. The current trial used CFD-
based deposition analyses to generate the hypothesis of al-
tered deposition behavior using fine particles in one patient.
This finding also needs to be confirmed in a larger sample.
Overall the challenging and heterogeneous nature of
COPD calls for a more patient-centered approach taking into
account the specific phenotype. Further exploring the po-
tential of new imaging methods could result in a more op-
timized treatment for COPD patients, resulting in fewer
exacerbations and an improved quality of life.
Conclusions
The study showed that the administration of extrafine
BDP/F after 4–6 h leads to a significant improvement in lung
function parameters and hyperinflation as determined by
spirometry, body plethysmography, and functional respira-
tory imaging. Patients previously treated with ICS remained
stable despite the lower dose, while ICS naı¨ve patients im-
proved in terms of lobar hyperinflation. A significant im-
provement in SGRQ symptom score was noted. Patients
who improved in terms of hyperinflation also improved their
MMRC dyspnea score. FRI seems to be a sensitive bio-
marker to detect clinically relevant changes that are not
detected by spirometry. The next step is to confirm these
findings in a controlled trial.
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